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International comparisons of acute myocardial infarction
Sheng-Chia Chung and colleagues1 report in The Lancet 
that, in their comparison of short-term outcomes in 
patients with acute myocardial infarction, unadjusted 
30-day mortality was more than a third higher in the 
UK than in Sweden during 2004–10. They suggest that 
this diﬀ erence is due largely to the divergent speed of 
implementation of policy initiatives to improve care. 
Chung and colleagues compared the UK data with those 
for Sweden because the two countries have similar health 
systems for, and spending on, acute myocardial infarction, 
but diﬀ usion of evidence-based changes to practice and 
new technologies has been notably quicker in Sweden.
Records for 119 786 patients in Sweden and 391 077 
in the UK were assessed. This fundamental prognosis 
research,2 which used whole-country data, showed 
much higher unadjusted mortality in patients with acute 
myocardial infarction in the UK than in Sweden: 30-day 
mortality was 10·5% (95% CI 10·4–10·6) in the UK and 
7·6% (7·4–7·7) in Sweden. The UK to Sweden standardised 
mortality ratio was 1·37 (1·30–1·45), which suggests 
that more than 11 000 deaths due to acute myocardial 
infarction might have been avoided during the period 
of the study. Importantly, although the diﬀ erence in 
mortality rates decreased over time, mortality was always 
higher in the UK, even in clinical subgroups such as 
those deﬁ ned by troponin concentration or ST-segment 
elevation. After standardisation for the Swedish casemix 
by use of a 17-variable model that took into account 
patients’ risk at baseline, UK 30-day mortality decreased 
by around 3%. This ﬁ nding suggests that factors from the 
point of ﬁ rst medical contact to 30 days from hospital 
admission diﬀ erentially aﬀ ect outcomes.
Chung and colleagues explored what factors might 
account for the international diﬀ erences in mortality. 
Their ﬁ ndings imply that between-country diﬀ erences in 
the use and dissemination of treatments recommended 
in guidelines was an important factor, as they noted that 
in the UK the uptake of primary percutaneous coronary 
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intervention (PCI) was lower at the starting point and 
prescribing rates for β blockers at discharge were lower 
than in Sweden.
Implementation of cardiovascular evidence-based 
practice in the UK has been reported to lag behind that 
of other countries. Laut and colleagues3,4 compared 
diﬀ usion of primary PCI across countries in the 
European Union and found that England was a late 
and low adopter. Yet, in Chung and colleagues’ study,1 
prescription of statins and angiotensin-converting-
enzyme inhibitors or angiotensin-receptor blockers at 
discharge was greater in the UK than in Sweden, which 
suggests that unless primary PCI and β blockers have a 
stronger association with survival than these treatments, 
other factors might lead to diﬀ erences in mortality. 
Although estimates equally favoured reduced 30-day 
mortality for primary PCI over that for thrombolysis 
in Sweden and the UK, in line with other studies,5 the 
associations between statins, angiotensin-converting-
enzyme inhibitors, and angiotensin-receptor blockers 
are not provided by the authors. Moreover, if the UK 
had adopted Swedish levels of use of primary PCI and 
β blockers, the standardised mortality ratio would only 
have reduced to 1·31, with primary PCI leading to around 
2000 and β blockers to less than 50 lives saved over the 
7 years of study. When the use of in-hospital treatments 
was considered in addition to casemix, the standardised 
mortality ratio decreased but did not reach unity.
The restricted improvement in standardised mortality 
ratio after adjustment for imbalanced treatments 
suggests that factors outside hospital-based cardiac 
interventions are also important. Indeed, Chung and 
colleagues’ study highlights the similarities between 
the UK and Sweden for thrombolysis and primary PCI 
process measures and that, overall, reperfusion rates 
were higher in the UK than in Sweden (77% vs 71%). 
The diﬀ erence in mortality rates, however, was upheld 
after matching by propensity score. This ﬁ nding is not 
surprising because the scores were derived from the 
same 17-factor model. For these reasons, unmeasured 
factors, such as imbalanced case ascertainment, 
unmeasured confounders, non-modelled covariates or 
missing data, and hospital care systems are probably 
responsible for the international diﬀ erence in mortality.
Aspects of health care, such as a patient’s appro-
priateness for therapy and drug adherence, might have 
diﬀ ered between the UK and Sweden. These data, which 
are not routinely collected in national electronic health-
care records, could have inﬂ uenced the UK mortality 
rates. In an attempt to mitigate bias due to absent 
data in one source but recorded elsewhere, the authors 
imputed missing data. This approach, however, is 
unlikely to have alleviated all systematic bias and would 
not account for data missing by design. The modelling of 
latent classes could have oﬀ ered greater insight into the 
eﬀ ects of unmeasured factors. Furthermore, the authors 
undertook an asymmetric analysis intended to assess 
what would have happened if UK patients had been 
transferred to Sweden, but the results of a bi-directional 
simulation might have been more informative. 
Nonetheless, through highlighting the prospect 
of a substantial excess of deaths in the UK compared 
with Sweden, Chung and colleagues have drawn 
our attention to the need for further comparative 
eﬀ ectiveness research for acute myocardial infarction. 
Eﬀ orts to improve cardiovascular outcomes in the UK 
should, therefore, concentrate on data enhancement 
through the linkage of electronic health-care records and 
the early and systematic implementation of evidence-
based therapies across the National Health Service. The 
authors reveal large international inequalities in the 
management and outcomes for these patients. Despite 
substantial reductions in early mortality rates after acute 
myocardial infarction, cardiovascular disease remains 
one of the biggest killers in developed countries.6,7 The 
prevention of premature cardiovascular death must, 
therefore, continue to be a priority for research.
CT scan showing stents (yellow) in coronary artery
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Prevention of varicella: time for two-dose vaccination
Live-attenuated varicella zoster virus (VZV) vaccines 
have been available for decades, but their potential to 
reduce disease worldwide has not been fully realised. 
Few countries have incorporated varicella vaccination 
into public programmes, even though rapid and large 
decreases in varicella deaths and admissions have been 
achieved in the USA and Australia.1,2 One reason for 
reluctance to vaccinate is that, despite high eﬃ  cacy of 
88–100% reported in the randomised controlled trials of 
one-dose live-attenuated monovalent varicella vaccines 
in children (Varilrix, GSK3 and Varivax, Merck4), ﬁ eld 
eﬀ ectiveness has turned out to be lower at 72–81%.5,6 In 
view of persisting disease transmission, some countries, 
such as the USA and Germany, now recommend a two-
dose schedule. Frustratingly, a paucity of empirical 
data on extent of enhanced protection expected from 
a second vaccination7 has made estimation of cost-
eﬀ ectiveness diﬃ  cult. This absence of information has 
been the main reason for countries such as Australia 
continuing a one-dose programme.8
In The Lancet, Roman Prymula and colleagues9 present 
results of the ﬁ rst randomised clinical trial to assess 
protection against varicella of two vaccine doses, using 
the four-in-one live-attenuated measles-mumps-rubella-
varicella (MMRV; Priorix-Tetra, GSK) vaccine. Although 
MMRV vaccines have been approved since the mid-
2000s, protection was assumed only on the basis of much 
the same immunogenicity as the component vaccines. 
This industry-funded study was done in 5803 toddlers 
aged 12–22 months across ten European countries where 
varicella remains endemic. Participants were divided into 
three groups; all children received consecutive doses of 
study vaccines given 6 weeks apart, thereby controlling 
for the number of injections. The ﬁ rst group received 
two doses of MMRV; the second group had ﬁ rst a dose 
of measles-mumps-rubella (MMR; Priorix, GSK) vaccine 
followed by monovalent varicella vaccine (Varilrix, GSK); 
and the third (control) group had two doses of MMR. 
Strengths of the study include 3 years of active 
follow-up (during which about 20% of all children 
reported exposure to varicella) and virological case-
conﬁ rmation using VZV-PCR. Eﬃ  cacy of one dose of 
varicella vaccination was in line with, if not a little 
lower than, expectations at 65·4% (97·5% CI 57·2–72·1) 
against disease of any severity and 90·7% (85·9–93·9) 
against moderate–severe disease, whereas two-dose 
MMRV prevented varicella in 94·9% (92·4–96·6) of 
children and was almost completely protective against 
moderate–severe disease (99·5% [97·5–99·9]). The risk 
of breakthrough varicella (deﬁ ned as wild strain varicella 
occurring more than 42 days after vaccination) was 
6·9 times (95% CI 4·9–9·8) less likely with two doses 
of MMRV than with one dose of varicella vaccine. As 
expected, immunogenicity of two-dose vaccination 
compared with one dose was also greater, at 42 days 
after vaccination and persisting for 2 years of follow-up.
This study reinforces that in most vaccine recipients, 
irrespective of receipt of one or two doses, varicella 
is a mild disease with fewer and less severe varicella 
lesions and fever than occurs in unvaccinated children. 
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